​Press Release

Aug 28, 2026

Pleryon Therapeutics Completes Australia’s TGA Clinical Trial Notification to Initiate First-in-Human Clinical Trial for its Lubricin-Inspired Polymer in Osteoarthritis

Jul 30, 2026

Pleryon Therapeutics Completes Part 1 of First-in-Human Clinical Trial for Dry Eye Disease

Jun 4, 2026

Pleryon Therapeutics Begins First-in-Human Clinical Trial for Dry Eye Disease

Jan 23, 2026

Pleryon Therapeutics Receives Approval from Health Canada to undertake a first-in-human clinical trial for its Lubricin-inspired Polymer P002 in Dry Eye Disease at CORE, University of Waterloo

Oct 12, 2025

Pleryon Therapeutics Appoints Global Dry Eye Experts Prof. Lyndon Jones and Prof. Fiona Stapleton as Scientific Advisors

Aug 22, 2025

Pleryon Therapeutics Completes 35M RMB Series A Financing to Accelerate Clinical Development of Innovative Therapies for Osteoarthritis and Dry Eye Disease

Jan 18, 2024

Seqens Partners with Pleryon to Develop and Manufacture an Innovative GMP Polymer to Treat Osteoarthritis

May 5, 2023

Pleryon Therapeutics Received Gold Medal with Congratulations of the Jury at the 48th International Exhibition of Inventions Geneva

Nov 8, 2022

Pleryon Therapeutics Announces Global Exclusive License Agreement for a Novel Therapeutic Polymer for the Treatment of Osteoarthritis

Apr 1, 2022

Pleryon Therapeutics Announced Securing Closed to 100 Million RMB in A Pre-A Funding Round

Aug 9, 2021

Pleryon Therapeutics Joints JLABS@Shanghai